Apexigen, Inc. Common Stock
APGN
APGN was delisted on the 22nd of August, 2023.
15 hedge funds and large institutions have $2.16M invested in Apexigen, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 5 closing their positions.
60% more call options, than puts
Call options by funds: $32K | Put options by funds: $20K
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less funds holding
Funds holding: 18 → 15 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
75% less capital invested
Capital invested by funds: $8.52M → $2.16M (-$6.36M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mercer Global Advisors
Denver,
Colorado
|
+$85K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$23.1K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$19.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.04K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$741 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$52.2K |
| 2 |
Two Sigma Investments
New York
|
-$38K |
| 3 |
Jane Street
New York
|
-$32.4K |
| 4 |
Fifth Third Bancorp
Cincinnati,
Ohio
|
-$4K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1K |
APGN Hedge Fund Activity: Q4 2022 in Review
15 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Apexigen, Inc. Common Stock (APGN) for Q4 2022, worth a combined $2.16M — down 75% from $8.52M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of APGN and 2 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 4 added.
The largest buyer was Mercer Global Advisors, opening a new position worth an estimated $85K. The largest seller was Citadel Advisors, cutting an estimated $52.2K.
- 15 institutional investors held Apexigen, Inc. Common Stock (APGN) as of Q4 2022, down from 18 in Q3 2022.
- Funds reported $2.16M of Apexigen, Inc. Common Stock stock for Q4 2022, down 75% quarter-over-quarter.
- 2 funds opened new Apexigen, Inc. Common Stock positions in Q4 2022 and 5 closed out, a net change of -3 holders.
- The largest Apexigen, Inc. Common Stock buyer in Q4 2022 was Mercer Global Advisors, an estimated $85K added.
- The largest Apexigen, Inc. Common Stock seller in Q4 2022 was Citadel Advisors, an estimated $52.2K sold.
Based on aggregated 13F filings for Q4 2022.